Lyell Immunopharma, Inc.
LYEL
$8.69
-$0.89-9.29%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -36.36% | -67.65% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -36.36% | -67.65% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -36.36% | -67.65% | |||
| SG&A Expenses | -3.28% | 23.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 1.88% | -96.85% | |||
| Total Operating Expenses | -9.18% | 22.19% | |||
| Operating Income | 9.18% | -22.25% | |||
| Income Before Tax | 72.81% | -330.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 72.81% | -330.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 72.81% | -330.51% | |||
| EBIT | 9.18% | -22.25% | |||
| EBITDA | 7.20% | -23.77% | |||
| EPS Basic | 74.20% | -294.25% | |||
| Normalized Basic EPS | 14.24% | -15.85% | |||
| EPS Diluted | 74.20% | -294.25% | |||
| Normalized Diluted EPS | 14.24% | -15.85% | |||
| Average Basic Shares Outstanding | 5.41% | 9.22% | |||
| Average Diluted Shares Outstanding | 5.41% | 9.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||